The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp41 plays an important role in the virus entry. During the process of fusion between the viral and target cell membranes, the N-and C-terminal heptad repeat (HR) regions of the gp41 extracellular domain associate to form a 6-helical bundle, corresponding to the fusion-active gp41 core. Any compound that blocks the gp41 6-helix bundle formation between the N-and C-peptides, which are derived from the N-and C-terminal HR regions, respectively, may inhibit HIV-1 mediated membrane fusion. Based on this principle, we previously established a sandwich enzyme-linked immunosorbent assay (ELISA) for drug screening by using the N-peptide N36 and the Cpeptide C34 and a monoclonal antibody (NC-1) which specifically recognizes the gp41 6-helix bundle. In the present study, a fluorescence-linked immunosorbent assay (FLISA) was developed by using fluorescein isothiocyanate (FITC)-conjugated C34 to replace C34 and by directly detecting fluorescence intensity instead of more complicated enzymatic reaction. Compared with the sandwich ELISA, this FLISA has similar sensitivity and specificity, but it is much more rapid, economic and convenient. Using an Integrated Robotic Sample Processing System, this assay has been applied for high-throughput screening of organic compounds on a large scale for HIV-1 fusion inhibitors targeting gp41. (Journal of Biomolecular Screening 2003:685-693) 
INTRODUCTION
I NFECTION BY THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) involves fusion of the viral envelope with the target cell membrane, followed by transfer of viral genetic material into the target cell. HIV-1 envelope glycoprotein (Env) transmembrane subunit gp41 plays an important role in the membrane fusion and serves as an important target for development of HIV-1 fusion inhibitors. [1] [2] [3] In native state, gp41 and Env surface subunit gp120 is noncovalently associated to a trimeric complex. 4 The fusion process is initiated by gp120 binding to a CD4 molecule and then to one of a group of chemokine coreceptors, such as CXCR4 or CCR5, on CD4 + target cells. 5, 6 The receptor-induced conformational changes in gp120 allow the conformation of gp41 to shift from a native state to an unstable prefusogenic state and fi-nally to a stable fusion-active state, in which the N-terminal heptad repeat (NHR) region and C-terminal heptad repeat (CHR) region of gp41 form a 6-helix bundle. 7 The process of 6-helix bundle formation produces energy and brings the viral and target cell membranes into proximity for fusion. 4 Crystallographic studies confirmed that the 6-helix bundle is the gp41 core structure of gp41, consisting of 3 NHR helices as the central trimeric coiled coil and 3 CHR helices packed obliquely in an antiparallel configuration into the highly conserved hydrophobic grooves on the surface of the central coiled coil. [8] [9] [10] Peptides derived from the NHR and CHR regions of gp41, named N-peptide and C-peptide, respectively, have potent inhibitory activity on HIV-1-mediated membrane fusion. [11] [12] [13] [14] These peptides are believed to interact with the counterpart regions in gp41 and block the association between the gp41 NHR and CHR regions to form fusion-active core structure. [1] [2] [3] [4] [8] [9] [10] 14 DP-178 (also named T-20, enfuvirtide, FUZEON™), one of the C-peptides consisting of 36 amino acid residues (aa 638 to 673), is the first member of a new class of antiretroviral agents called fusion inhibitors, which was recently approved by the U.S. Food and Drug Administration for treatment of infection by HIV-1, including the strains that are resistant to the reverse transcriptase inhibitors and protease inhibitors. [15] [16] [17] However, the peptidic drug T-20 has several limita-tions for clinical applications, for example, lack of oral availability and high cost of production. Alternatively, small molecule compounds with similar inhibitory activity against HIV-1 fusion are much more attractive.
A model system for the gp41 6-helix bundle formation was established by mixing the gp41 N-and C-peptides, N36 and C34, respectively, at equal molar concentration. 18 Using this model system and a monoclonal antibody (mAb) NC-1, which specifically recognizes the conformational epitope on the gp41 6-helix bundle, we have developed a sandwich enzyme-linked immunosorbent assay (ELISA) to screen for antiviral compounds that block the interaction between the N-and C-peptides to form the fusion-active gp41 core. 19 Although this assay is specific and sensitive, it is not convenient for high-throughput screening (HTS) because it has to be carried out at 37°C and double antibodies and enzymatic reaction system are needed. In the present study, we developed a simple and rapid fluorescence-linked immunosorbent assay (FLISA) using fluorescein isothiocyanate (FITC) conjugated C34 and automated this assay using an integrated robotic sample processing system for HTS of HIV-1 fusion inhibitors that interfere with the gp41 6-helix bundle formation from chemical libraries consisting of hundreds of thousands of compounds.
MATERIALS AND METHODS

Cells and reagents
MT-2 cells and H9/HIV-1 IIIB cells were obtained from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program contributed by Drs. D. Richman and R. Gallo, respectively. All cells were maintained in RPMI-1640 containing 10% fetal bovine serum and appropriate antibiotics.
The rabbit polyclonal antibody and mouse monoclonal antibody specific for the gp41 6-helix bundle were prepared and characterized as previously described. 20 Normal mouse IgG 2a was purchased from R&D Systems Inc. (Minneapolis, MN).
Peptides N36 (gp41 residues 546-581), C34 (gp41 residues 628-661), C34-FITC (FITC was added to the N-terminus of C34), V3 loop peptide (global consensus, 35-mer), fusion peptide (gp41 residues 519-542), and T22 (a peptidic CXCR4 antagonist) were synthesized by a standard solid-phase FMOC method using Advanced Chemtech 396 synthesizer with Fmoc-amino acids and HBTU as the coupling agent. The N-termini of the peptides were acetylated, and their C-termini were amidated. All peptides were purified to homogeneity by reverse-phase high-performance liquid chromatography. The identity of the purified peptides was confirmed by mass spectrometry (PerSeptive Biosystems). Peptide concentrations were determined by absorbance at 280 nm in 6 M GuHCl.
ADS-J1 was purified from the crude materials provided by Ciba Specialty Chemicals Corp. (High Point, NC). XTT formazan (XTT-F) was prepared as previously described. 21 Soluble CD4 was purchased from R&D Systems Inc. Azidothymidine (AZT), an HIV-1 reverse transcriptase inhibitor, was purchased from Boehringer Mannheim (Indianapolis, IN). Saquinavir, an HIV-1 protease inhibitor, was obtained through the AIDS Research and Reference Program, National Institute of Allergy and Infectious Diseases, NIH.
FLISA
This FLISA was established based on the principle that N36 and C34-FITC are able to form a 6-helix bundle, which can be captured by a conformation-specific mAb NC-1 coated onto the bottom of wells of a plate. Thus, the fluorescence intensity can be detected directly by a fluorescence microplate reader. If a testing compound interacts with the N-or C-peptide and blocks the 6helix bundle formation, the isolated C34-FITC and N36 are removed by washes, resulting in a decrease of fluorescence intensity ( Fig. 1) . Therefore, the percent inhibition of the compound on the 6-helix bundle formation can be calculated based on the levels of reduction of the fluorescence intensity mediated by the compound.
Briefly, mAb NC-1 (0.8 µg/well) in 0. In the presence of an inhibitor, the compound may bind to N36 or C34 to block the 6-helix bundle formation. Therefore, no fluorescencecontaining 6-helix bundle is captured, resulting in much lower fluorescence intensity than the control (A). In this way, the inhibitors can be identified.
overnight. After removal of the coating buffer, the plate was blocked with phosphate buffered saline (PBS) containing 5% horse serum and 0.05% Tween-20 at room temperature for 2 h. Twenty-five µl N36 (2 µM in PBS) and 50 µl compound at graded concentration in PBS were added into the precoated wells and incubated at room temperature for 30 min. Then 25 µl C34-FITC (2 µM in PBS) was added and incubated for another 30 min at room temperature. After washing extensively with washing buffer (PBS containing 0.05% Tween-20), 150 µl PBS was added to each well of the plate. Shaking gently for 5 min, the fluorescence intensity was read by the Ultra 384 reader (Tecan U.S., Inc., Durham, NC). The percentage of inhibition of the 6-helix bundle formation by a compound was calculated as previously described 22 : % inhibition = [1 -(E -N)/(P -N)] × 100, where E represents fluorescence intensity in the presence of a compound and P represents fluorescence intensity in the absence of a compound. N corresponds to the wells where neither compound nor N36 was added.
HTS assay for inhibitors against 6-helix bundle formation between N36 and C34-FITC
The procedures of the FLISA described above were applied to an HTS assay for screening of compounds that inhibit 6-helix bundle formation between N36 and C34-FITC. Plate coating, blocking, washing, addition of reagents, and plate reading were all processed with an integrated robotic sample processing system (Tecan U.S., Inc.), which consists of a robotic sample processor (model: Genesis Logistic Workstation) with a 96-well (extensible to 384well) microplate configuration and a multifunctional reader (model: Ultra 384). The system was controlled by Gemini V3.5 and Magellan V3.0 software. The data were automatically collected and analyzed.
Sandwich ELISA
The sandwich ELISA for testing whether a compound inhibits the gp41 6-helix bundle formation was described previously. 19 Briefly, N36 (2 µM in PBS) was preincubated with a compound at graded concentrations in PBS at 37°C for 30 min, followed by addition of C34 (2 M in PBS). After incubation at 37°C for 30 min, the mixture was added to wells of 96-well polystyrene plates (Immulon I, Dynatech Laboratories, Inc., Chantilly, VA), which were precoated with IgG (1 µg/well) purified from rabbit antisera directed against the gp41 6-helix bundle. Then, the mAb NC-1, biotin-labeled goat-anti-mouse IgG (Boehringer Mannheim), streptavidin-labeled horseradish peroxidase (Zymed, San Francisco, CA), and the substrate, 3,3′,5,5′-tetramethylbenzidine (Sigma Chemical Co., St Louis, MO) were added sequentially. Absorbance at 450 nm was determined spectrophotometrically by an ELISA reader (Multiskan MCC/340, Labsystems, Helsinki, Finland).
Native polyacrylamide gel electrophoresis (Native-PAGE) and fluorescence native polyacrylamide gel electrophoresis (FN-PAGE)
Precast Tris-Glycine gels (18%) and Novex X-Cell II Mini Cell (Invitrogen, Carlsbad, CA) were used for Native-PAGE and FN-PAGE. N36 was incubated with C34 or C34-FITC equimolarly at 37°C for 30 min (the final concentration of the peptide was 50 µM), then Tris-Glycine native sample buffer (Invitrogen) was added at a ratio of 1:1. The mixture was loaded to 10 × 1.0 mm precast gel (25 µl each well). Electrophoresis was carried out with 125 V at room temperature for about 120 min. After electrophoresis, the gel was then stained with Coomassie blue. For FN-PAGE, before Coomassie blue staining, the gel was imaged and analyzed by FluorChem 8800 Imaging System (Alpha Innotech Corp., San Leandro, CA) with the transillumination UV light source of 302 nm as exciting wavelength and the fluorescence filter of 520 nm as emission wavelength.
HIV-1-mediated cell fusion
A dye transfer assay was used for detection of HIV-1-mediated cell fusion as previously described. 23 H9/HIV-1 IIIB cells were labeled with a fluorescent reagent, calcein AM (Molecular Probes, Inc., Eugene, OR) and then incubated with MT-2 cells (ratio = 1:10) in 96-well plates at 37°C for 2 h in the presence or absence of compounds tested. The fused and unfused calcein-labeled HIV-1infected cells were counted under an inverted fluorescence microscope (Zeiss, Germany) with an eyepiece micrometer disc. The percentage of inhibition of cell fusion by the compounds was calculated as previously described, 23 and IC 50 (the concentration for 50% inhibition) values were calculated using the computer program Calcusyn, kindly provided by Dr. T. C. Chou (Sloan-Kettering Cancer Center, New York). 24
Quality evaluation of the HTS assay
The data were analyzed by calculation of some parameters. A simple statistical parameter, Z factor (Z), was applied for quality evaluation of the HTS assays. Z factor was calculated by using the following formula: Z = 1 -[3 × (SD signal + SD background ) / (M signal -M background )], in which M signal , M background , SD signal , and SD background represent the mean (M) and standard deviation (SD) for signal and background, respectively. 25, 26 The larger the Z-factor value of an assay, the higher the quality of the assay for HTS. For example, 0.5 > Z > 0 suggests that it is a doable assay, whereas 1 > Z > 0.5 indicates that it is an excellent assay. 26 Signal-to-background (S/B) and signal-to-noise (S/N) were also calculated 25 
RESULTS
Conjugation of FITC to C34 did not affect its activity on HIV-1-mediated cell fusion and the 6-helix bundle formation with N36
C34-FITC is a critical reagent required in this FLISA. The effect of FITC conjugation to the N-terminus of C34 was investigated by using a series of assays. In cell fusion assay, C34-FITC and unconjugated C34 had similar inhibitory activity on HIV-1mediated cell fusion ( Fig. 2A) . In sandwich ELISA, FITCconjugated C34, like C34, also formed the 6-helix bundle with N36 (Fig. 2B) . In Native-PAGE, we previously demonstrated that a band of the 6-helix bundle formed by N36 and C34 could be revealed and that this band was reactive to the mAb NC-1 (unpublished data). Here we confirmed that both C34 (Fig. 2C ) and C34-FITC ( Fig. 2D ) could interact with N36 to form the 6-helix bundle (upper band). Because the migration speed of a molecule depends on its size and net charge in Native-PAGE and C34-FITC contains more negatively charged groups than C34, the 6-helix bundle containing C34-FITC moved faster than that containing C34 (Figs. 2C and 2D). With a fluorescence imaging system, 2 fluorescence bands were revealed in the lane where the mixture of N36 and C34-FITC was added ( Fig. 2E) . Consistent with the result in Figure 2D , the lower band was C34-FITC whereas the upper band corresponded to the 6-helix bundle formed by N36 and C34-FITC. This band should not be the isolated N36 because N36 contained no fluorescence. These results suggest that C34-FITC has similar activity against HIV-1-induced cell fusion and to form the gp41 6-helix bundle formation as C34.
Detection of the 6-helix bundle formed between N36 and C34-FITC by FLISA
Then we determined whether the 6-helix bundle formation between N36 and C34-FITC could also be detected by FLISA using the mAb NC-1 coated fluorescence microplate. As shown in Figure 3 , high fluorescence intensity was detected in the wells where N36 and C34-FITC were mixed at equimolar concentration, whereas the isolated C34-FITC showed only background fluorescence intensity. The NC-1 isotype-matched normal mouse IgG 2a could not capture N36/C34-FITC complex, indicating that this assay is specific for detecting the formation of the 6-helix bundle.
Identification of appropriate blocking reagents to reduce the nonspecific binding and increase the signal-to-background ratio
In FLISA, blocking reagents are important factors affecting the fluorescence intensity. As shown in Figure 4 , nonfat milk significantly reduced the fluorescence intensity of N36/C34-FITC complex, although it is an excellent blocking reagent in the sandwich ELISA. Therefore, nonfat milk should not be used in FLISA. Other blocking reagents including horse serum, goat serum, and bovine serum albumin were suitable to this assay. We choose 5% horse serum in PBS as the blocking reagent because the highest fluorescence intensity and the signal-to-background ratio were obtained when it was used.
Optimization of reaction temperature and duration
In the sandwich ELISA, all the incubations are performed at 37°C. 19 For HTS, it would be much more convenient if the incubations are carried out at room temperature than at 37°C because in the latter case, all the plates have to be transferred into and out of a 37°C incubator frequently. This procedure may introduce a high coefficient of variation. Here we compared the results obtained from FLISA performed at 37°C and room temperature (average about 23°C), respectively. For incubation at 37°C, the fluorescence intensity of the positive and negative controls was 50,997 ± 2413 and 3636 ± 57, respectively, whereas for incubation at room temperature, it was 53,433 ± 2674 and 3931 ± 216, respectively ( Fig. 5A ), suggesting that similar results were obtained when FLISA was carried out at 37°C and at room temperature. Therefore, we selected room temperature as the optimal incubation temperature for the screening assay.
In the sandwich ELISA, it takes 1 h for each incubation step. To shorten the experiment duration, the reaction time (at room temperature) was reduced from 60 min to 30 min and the results were compared. For 60-min incubation, the fluorescence intensity of the positive and negative controls was 52,170 ± 2118 and 4021 ± 245, respectively, whereas for 30-min incubation, those were 53,037 ± 2509 and 3781 ± 59, respectively (Fig. 5B ). There was no significant difference between the assays with incubation duration for 60 and 30 min. Study on the kinetics of reaction indicated that the fluorescence intensity increased with the extension of incubation time but reached a plateau at 30 min (data not shown), suggesting that 30 min is enough for completion of each reaction. Therefore, we selected 30 min as the optimal incubation duration for this assay.
Optimization of N36 and C34-FITC concentrations
To obtain the optimal concentrations of N36 and C34-FITC, the 2 peptides at different concentrations and different ratios were tested by crisscross serial-dilution assay. As shown in Figure 6 , very low or no responses could be detected when the concentrations of N36 were at 0.25 µM or lower. With the increasing concentrations of N36, the fluorescence intensity elevated in a dosedependent manner. When N36 was used at 2 µM, the fluorescence intensity was correlated with the concentration of C34-FITC at the range between 0.25 and 2 µM. At 2 µM of C34-FITC (ratio of C34-FITC/N36 = 1), the fluorescence intensity reached to more Positive and negative controls (with and without N36, respectively) were detected at 37°C and 23°C (room temperature), respectively. (B) Positive and negative controls were assessed at room temperature for 30 min and 60 min, respectively. Each data point was measured in triplicate and presented as the average ± SD. than 90% of the peak values. Therefore, we selected 2 µM of both N36 and C34-FITC as the optimal concentrations of the N-and Cpeptides used in the FLISA screening assay.
HTS of HIV-1 Fusion Inhibitors
Specificity and sensitivity of FLISA-based screening assay
To determine the specificity of the FLISA-based screening assay, unconjugated C34 was used for competitive inhibition of the interaction between C34-FITC and N36 to form the 6-helix bun-dles. Unconjugated peptides from another region of gp41 (e.g., fusion peptide) and from gp120 (e.g., V3 loop peptide 27 ) were included as controls. As shown in the Figure 7 , C34 inhibited C34-FITC interacting with N36 in a dose-dependant manner with an IC 50 about 0.36 µM. The final concentration of C34-FITC added is about 0.5 µM, suggesting both C34 and C34-FITC have similar efficiency to form the 6-helix bundle. Fusion peptide and V3 loop peptide could not competitively inhibit the 6-helix bundle formation between C34-FITC and N36, suggesting that this FLISA is specific for the peptidic inhibitors that block the 6-helix bundle formation. The specificity of this screening assay was further determined later by comparing the inhibitory activity of nonpeptidic anti-HIV compounds with distinct mechanism of action.
To test the sensitivity of FLISA, we compared the inhibitory activity of ADS-J1 on the 6-helix bundle formation detected by the FLISA and the sandwich ELISA, respectively. As shown in Figure 8 , the IC 50 values obtained by the FLISA and the sandwich ELISA were 3.55 ± 0.23 µg/ml and 3.20 ± 0.12 µg/ml, respectively (no significant difference), suggesting that FLISA has similar sensitivity as the sandwich ELISA in identification of compounds that interfere with the gp41 6-helix bundle formation.
Automation of FLISA for HTS for compounds that interfere with the gp41 6-helix bundle formation using an integrated robotic sample processing, detection, and analyzing system
After optimization, the FLISA was adapted to an automatic HTS assay using Genesis Logistic Workstation (Tecan U.S., Inc.). We first tested the positive and negative controls (with and without N36, respectively) with this system and compared the well-to-well variation. As shown in Figure 9 , the coefficient of variation was 5.4% for the positive controls and 5.3% for the negative controls.
The signal-to-background ratio was 10.9, the signal-to-noise ratio was 16.7, and the Z factor was 0.80, suggesting that this assay with excellent quality is suitable for HTS. 25, 26 Several peptidic and nonpeptidic HIV-1 fusion inhibitors, such as C34, 8, 18 ADS-J1, 28 and XTT formazan, 21 have been identified.
To determine the specificity of the FLISA-based HTS assay, C34, ADS-J1, XTT formazan, and several anti-HIV-1 agents with different mechanisms of action were randomly distributed (10 µg/ml, in triplicate) into the wells of a 96-well plate, and their inhibitory activity on 6-helix bundle formation was detected using this robotic system. As shown in Figure 10 , C34, ADS-J1, and XTT formazan inhibited the formation of 6-helix bundle, whereas T22 (a peptidic CXCR4 antagonist), 29 soluble CD4 (a gp120 receptor), 30, 31 AZT (an HIV-1 reverse transcriptase inhibitor), and saquinavir (an HIV-1 protease inhibitor) had no significant inhibition. These results are consistent with those obtained by using sandwich ELISA. 19 It suggests that the HTS assay developed in the present study is a reliable, convenient, and suitable method for screening organic compounds on a large scale. We are now using this HTS assay for screening a commercial chemical library consisting of more than 50,000 compounds for HIV fusion inhibitors targeting gp41.
DISCUSSION
In our previous studies, we demonstrated that a 6-helix bundle, representing the HIV-1 gp41 fusion-active core, modeled by the Nand C-peptides derived from the gp41, could be detected by a sandwich ELISA 19 using a conformation-specific mAb NC-1. 20 This assay could be used for screening for compounds that block the formation of the gp41 6-helix bundle and inhibit HIV-1mediated cell fusion. Although this sandwich ELISA is specific and sensitive for identification of HIV-1 fusion inhibitors targeting gp41, it is difficult to be adapted for HTS using an integrated robotic sample processing system because of several limitations. First, it is time consuming, requiring about 6.5 h for a single screening cycle. Second, it is inconvenient because this assay has to be carried out at 37°C. The procedures may introduce higher experimental variation during the frequent transportation of the plates into and out of the 37°C incubators. Third, it is expensive because in this assay, 3 antibodies (polyclonal and monoclonal antibodies against N36/C34 complex and biotin-conjugated antimouse IgG) and enzyme reaction system are required. Those are costly reagents. Finally, it is incapable of screening peptides derived from the gp41 CHR region and their analogues because these peptides may interact with N36 to form a conformation that can be captured by mAb NC-1.
One of the solutions to overcome the above shortcomings is to replace the sandwich ELISA with a FLISA, in which the antigens or antibodies are labeled with a fluorescent agent. FLISA has been widely used for detection of antigens or antibodies. [32] [33] [34] [35] In the present study, we developed a FLISA as a new screening method after modification of the sandwich ELISA by 1) replacing C34 with FITC-conjugated C34, 2) using only 1 antibody (NC-1) instead of 3 antibodies, 3) detecting fluorescence intensity directly rather than measuring absorbance after enzyme reaction, 4) changing the incubation temperature from 37°C to room temperature, and 5) shortening the duration of each incubation step from 60 min to 30 min. Compared with the sandwich ELISA, this assay has several advantages: 1) much more rapid (the time for 1 screening cycle was shortened from 6.5 h to 1.5 h), 2) more convenient (experiment procedure was simplified from 5 steps to only 1 step after ad- dition of the mixture of the N-and C-peptides), 3) more economic (the cost was reduced by more than 70% because fewer reagents were used), and 4) capable of screening peptidic inhibitors derived from the gp41 CHR region. We demonstrated FLISA has similar specificity and sensitivity as the sandwich ELISA. After optimization of the experimental conditions, the FLISA was adapted for HTS using an integrated robotic sample processing system for automatic operation. Statistic analysis of the results of positive and negative controls indicated that this FLISA-based HTS system has excellent quality of assay for drug screening. We used this HTS assay for testing several anti-HIV-1 agents with distinct mechanisms of action, which were randomly distributed in a 96-well plate. The result showed that only those previously defined HIV-1 fusion inhibitors targeting gp41 blocked the 6-helix bundle formation, suggesting that this automatic FLISA is suitable for HTS to identify active compounds that interfere with the fusion-active gp41 core formation.
HTS of HIV-1 Fusion Inhibitors
In conclusion, this FLISA-based HTS assay is simple, rapid, robust, and economic. It may achieve a screening capacity of greater than 2000 compounds per day by using the 96-well plate format. This system is extensible to a 384-well plate format, with which we will be able to screen about 8000 compounds per day. We are now using this FLISA-based HTS system to screen chemical libraries on a large scale for identification of potential HIV-1 fusion inhibitors targeting gp41.
